Agios Pharmaceuticals

AGIO · NASDAQ

$36.64+$1.74 (+4.99%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $34.90

Latest news

Press releaseOct 20, 8:59 AM ETPRNewswire
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday
NewsSep 10, 8:02 AM ETAvi Kapoor
Limoneira Posts Downbeat Q3 Results, Joins Cooper Companies, Navan And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
Press releaseAug 6, 11:02 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
Press releaseJul 30, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
Press releaseJul 30, 6:30 AM ETGlobe Newswire
Agios Reports Second Quarter 2026 Financial Results and Provides Business Update
Press releaseJul 28, 5:24 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
NewsJul 21, 11:44 AM ETVandana Singh
Agios Reports Neutral Sickle Cell Data, Decides To Stop Development
Press releaseJul 21, 7:00 AM ETGlobe Newswire
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
NewsJul 7, 2:27 PM ETVandana Singh
Why Is Agios Pharma Stock Soaring Tuesday?
Press releaseJul 7, 7:00 AM ETGlobe Newswire
U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease
Press releaseJun 13, 9:00 AM ETGlobe Newswire
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
NewsJun 1, 5:05 AM ET
Agios Acquires Global Rights to Experimental Blood Disorder Drug From South Korea's Oscotec
Press releaseJun 1, 5:00 AM ETGlobe Newswire
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib
Press releaseMay 29, 7:00 AM ETGlobe Newswire
Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes
Press releaseMay 22, 10:18 AM ETBusiness Wire
Avanzanite Bioscience's Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia
NewsMay 22, 9:18 AM ET
Agios Pharmaceuticals Announces EU Marketing Authorization For PYRUKYND In Adults For Treatment Of Anemia
Press releaseMay 22, 9:15 AM ETGlobe Newswire
Agios' PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia
Press releaseMay 12, 9:30 AM ETGlobe Newswire
Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias
NewsApr 29, 7:11 AM ET
Earnings Scheduled For April 29, 2026
Press releaseApr 29, 6:30 AM ETGlobe Newswire
Agios Reports First Quarter 2026 Financial Results and Provides Business Update
NewsApr 20, 1:05 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
NewsApr 20, 10:08 AM ETAvi Kapoor
US Stocks Mixed; Cleveland-Cliffs Shares Fall After Q1 Results
Press releaseApr 1, 9:00 AM ETPRNewswire
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
NewsMar 31, 9:57 AM ETAvi Kapoor
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Press releaseMar 31, 9:00 AM ETPRNewswire
AGIO ALERT- The Gross Law Firm Has Commenced an Investigation on Behalf of Agios Pharmaceuticals, Inc. Shareholders Who Lost Money
Press releaseMar 25, 9:00 AM ETPRNewswire
AGIO STOCK ALERT: Levi & Korsinsky Notifies Agios Pharmaceuticals, Inc. Investors of an Ongoing Investigation
Press releaseMar 18, 9:00 AM ETPRNewswire
ATTENTION AGIO SHAREHOLDERS: Investors who lost money on Agios Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
Press releaseMar 17, 9:00 AM ETPRNewswire
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact The Gross Law Firm Regarding an Ongoing Investigation
Press releaseMar 11, 9:00 AM ETPRNewswire
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
Press releaseMar 10, 9:00 AM ETPRNewswire
Agios Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact The Gross Law Firm for Details- AGIO
Press releaseMar 4, 9:00 AM ETPRNewswire
Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - AGIO
Press releaseMar 3, 9:00 AM ETPRNewswire
Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact The Gross Law Firm Regarding Potential Securities Law Violations - AGIO
NewsFeb 12, 6:36 AM ET
Earnings Summary: Agios Pharmaceuticals Q4
Press releaseFeb 12, 6:30 AM ETGlobe Newswire
Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
NewsFeb 12, 6:11 AM ET
Earnings Scheduled For February 12, 2026
NewsJan 12, 7:19 AM ET
Agios Sets 2026 Growth Plan as FDA-Approved AQVESME Launches and New Trial Readouts Near
Press releaseJan 12, 7:00 AM ETGlobe Newswire
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth
NewsDec 26, 1:04 PM ETAvi Kapoor
Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday
NewsDec 24, 12:05 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsDec 24, 11:06 AM ETAvi Kapoor
Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday
NewsDec 24, 7:31 AM ETVandana Singh
FDA Approves Agios Drug For Thalassemia-Associated Anemia
NewsDec 24, 12:07 AM ETAvi Kapoor
UiPath, Ramaco Resources And 3 Stocks To Watch Heading Into Wednesday
NewsNov 19, 12:58 PM ETAvi Kapoor
Crude Oil Falls Over 2%; Lowe's Shares Gain After Q3 Results
NewsNov 19, 12:30 PM ETVandana Singh
Why Is Agios Pharmaceuticals Stock Sinking Today?
NewsNov 19, 12:06 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsNov 19, 7:05 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Press releaseOct 30, 6:30 AM ETGlobe Newswire
Agios Reports Third Quarter 2025 Financial Results and Provides Business Update
NewsOct 29, 3:02 PM ET
Earnings Outlook For Agios Pharmaceuticals

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday

Limoneira Posts Downbeat Q3 Results, Joins Cooper Companies, Navan And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

Agios Reports Second Quarter 2026 Financial Results and Provides Business Update

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

Agios Reports Neutral Sickle Cell Data, Decides To Stop Development

Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease

Why Is Agios Pharma Stock Soaring Tuesday?

U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

Agios Acquires Global Rights to Experimental Blood Disorder Drug From South Korea's Oscotec

Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib

Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes

Avanzanite Bioscience's Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia

Agios Pharmaceuticals Announces EU Marketing Authorization For PYRUKYND In Adults For Treatment Of Anemia

Agios' PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia

Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias

Earnings Scheduled For April 29, 2026

Agios Reports First Quarter 2026 Financial Results and Provides Business Update

12 Health Care Stocks Moving In Monday's Intraday Session

US Stocks Mixed; Cleveland-Cliffs Shares Fall After Q1 Results

Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky

Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

AGIO ALERT- The Gross Law Firm Has Commenced an Investigation on Behalf of Agios Pharmaceuticals, Inc. Shareholders Who Lost Money

AGIO STOCK ALERT: Levi & Korsinsky Notifies Agios Pharmaceuticals, Inc. Investors of an Ongoing Investigation

ATTENTION AGIO SHAREHOLDERS: Investors who lost money on Agios Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation

Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact The Gross Law Firm Regarding an Ongoing Investigation

Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

Agios Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact The Gross Law Firm for Details- AGIO

Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - AGIO

Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact The Gross Law Firm Regarding Potential Securities Law Violations - AGIO

Earnings Summary: Agios Pharmaceuticals Q4

Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Earnings Scheduled For February 12, 2026

Agios Sets 2026 Growth Plan as FDA-Approved AQVESME Launches and New Trial Readouts Near

Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth

Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday

12 Health Care Stocks Moving In Wednesday's Intraday Session

Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday

FDA Approves Agios Drug For Thalassemia-Associated Anemia

UiPath, Ramaco Resources And 3 Stocks To Watch Heading Into Wednesday

Crude Oil Falls Over 2%; Lowe's Shares Gain After Q3 Results

Why Is Agios Pharmaceuticals Stock Sinking Today?

12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Agios Reports Third Quarter 2025 Financial Results and Provides Business Update

Earnings Outlook For Agios Pharmaceuticals